Between-group minimally important change versus individual treatment responders is a research paper published in Quality of Life Research (2021). On theSindex it has a DataRank of 0. It has been cited 62 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: NIH/NIA Grant P30-AG021684.
National Institutes of Health
Grant: NIH/NIA Grant P30-AG059988
NIA NIH HHS
Grant: P30 AG021684
NIA NIH HHS
Grant: P30 AG059988
National Institutes of Health
Grant: 1P30AG059988-01A1
The Claude D. Pepper Older Americans Independence Center (OAIC) at Northwestern University
National Institutes of Health
Grant: 3P30AG021684-08S3
The Center for Health Improvement of Minority Elderly
FWCI
8.67
Citation Percentile
1.0%
Influential Citations
5
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 1 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 2 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 2 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 3 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 3 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 1 of Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study
Additional file 1 of Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study
Additional file 3 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 4 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 1 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 3 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 4 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 5 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 2 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 5 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 1 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis
Additional file 2 of Cost-effectiveness of a second opinion program on spine surgeries: an economic analysis